Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components

NCT02549222 is registered in ClinicalTrials.gov with Cerus Corporation as lead sponsor.

NCT NCT02549222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02549222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components
Lead sponsor
Cerus Corporation
Phase
Observational
Overall status
Completed
Start date
December 31, 2015
Completion date
May 31, 2021
Enrollment
2,291 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

transfusion related acute lung injury